Abu-Halaweh Sami, Obeidat Firas, Absalom Anthony R, AlOweidi Abdelkareem, Abeeleh Mahmood Abu, Qudaisat Ibrahim, Robinson Fay, Mason Keira P
Department of Anesthesia and ICU, Faculty of Medicine, University of Jordan and Jordan University Hospital, Amman, Jordan.
Department of Surgery, Faculty of Medicine, University of Jordan and Jordan University Hospital, Amman, Jordan.
Surg Endosc. 2016 Aug;30(8):3368-74. doi: 10.1007/s00464-015-4614-y. Epub 2015 Nov 5.
The primary aim of this pilot study was to determine whether the dexmedetomidine infusion initiated immediately after laparoscopic bariatric surgery, offers an advantage over a morphine infusion with respect to rescue morphine and paracetamol requirements over the first 24 post-operative hours.
Sixty morbidly obese adult patients scheduled for laparoscopic bariatric surgery were randomly assigned to receive an infusion of either 0.3 mcg/kg/h dexmedetomidine (Group D) or 3 mg/h Morphine (Group M) for 24 h immediately post-operatively. All patients received standardized general anesthesia and were evaluated and treated for pain in the intensive care unit by providers who were blinded to their treatment group. The primary outcome was the need for supplemental, "rescue" paracetamol (Dolargan. Hikma, Jordan) and morphine titrated to achieve visual analog scales (VAS) of <40 and <70, respectively.
A total of 60 patients (77 % female, mean age 33.5 years ± 9.5 and body mass index (BMI) 43.0 ± 4.5) were randomized to Group M and 30 to Group D. There were no significant differences in mean rescue paracetamol and morphine requirements. Mean total morphine requirements in Group D were 6.1 ± 3.1 mg, whereas 72.9 ± 2.2 mg in Group M (p < 0.0001).
An intravenous infusion of dexmedetomidine, initiated and continued for 24 h following laparoscopic bariatric surgery, can decrease the overall morphine requirements during this period. This pilot study demonstrated that the post-operative initiation of dexmedetomidine can be morphine sparing following laparoscopic bariatric surgery.
本初步研究的主要目的是确定在腹腔镜减肥手术后立即开始输注右美托咪定,在术后24小时内,与输注吗啡相比,在补救性吗啡和对乙酰氨基酚需求方面是否具有优势。
60例计划接受腹腔镜减肥手术的病态肥胖成年患者被随机分配,术后立即接受24小时的0.3微克/千克/小时右美托咪定输注(D组)或3毫克/小时吗啡输注(M组)。所有患者均接受标准化全身麻醉,并由对其治疗组不知情的医护人员在重症监护病房对疼痛进行评估和治疗。主要结局是需要补充“补救性”对乙酰氨基酚(多乐纲,希克玛,约旦)和滴定吗啡,以使视觉模拟评分(VAS)分别<40和<70。
共有60例患者(77%为女性,平均年龄33.5岁±9.5岁,体重指数(BMI)43.0±4.5)被随机分配至M组,30例至D组。补救性对乙酰氨基酚和吗啡的平均需求量无显著差异。D组的平均吗啡总需求量为6.1±3.1毫克,而M组为72.9±2.2毫克(p<0.0001)。
腹腔镜减肥手术后开始并持续24小时静脉输注右美托咪定,可降低该期间的总体吗啡需求量。本初步研究表明,腹腔镜减肥手术后开始使用右美托咪定可节省吗啡。